Trials / Completed
CompletedNCT03577470
An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate
Italian Retrospective and Prospective Observation of Antiretroviral Treatment in Patients Taking DarunavIr/cobicistAt Plus eMtricitabine and Tenofovir AlafeNamide fumaraTE - DIAMANTE
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 246 (actual)
- Sponsor
- Janssen-Cilag S.p.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the effectiveness of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), measured as virological response at Week 48 as per Food and Drug Administration (FDA) snapshot algorithm through collection of daily practice data in the Italian setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | D/C/F/TAF Fixed-Dose Combination (FDC) | Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study. |
Timeline
- Start date
- 2018-06-13
- Primary completion
- 2020-09-28
- Completion
- 2020-09-28
- First posted
- 2018-07-05
- Last updated
- 2024-10-15
Locations
18 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT03577470. Inclusion in this directory is not an endorsement.